Icosavax, Inc. ( ICVX) Stock. Should you Buy or Sell? $ 4.77
0.12 (2.45 %)
Icosavax, Inc. Analysis
Updated on 10-09-2022| Symbol | ICVX |
| Price | $4.77 |
| Beta | 0.000 |
| Volume Avg. | $201.61 thousand |
| Market Cap | $190.25 M |
| 52 Week Range | $4.0 - $41.98 |
Icosavax, Inc. opened the day at $4.77 which is +'2.45 % on yesterday's close. Icosavax, Inc. has a 52 week high of $41.98 and 52 week low of $4.0, which is a difference of $37.98. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $190.25 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Icosavax, Inc. for $190.25 M, it would take 15 years to get your money back. Icosavax, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Icosavax, Inc. Stock Forecast - Is Icosavax, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Neutral | |
| ROA Score | Neutral | |
| DE Score | Neutral | |
| PE Score | Sell | |
| PB Score | Buy | |
| Overall Recommendation | Buy |
Growth and Value
| PE Ratio | 47.700 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | -25.270 |
Valuing Icosavax, Inc.
| Price Book Value Ratio | 0.779 | Price To Book Ratio | 0.779 |
| Price To Sales Ratio | 103.374 | Price Earnings Ratio | -4.091 |
How liquid is Icosavax, Inc.
| Current Ratio | 20.891 |
| Quick Ratio | 20.412 |
Debt
| Debt Ratio | 0.066 | Debt Equity Ratio | 0.071 |
| Long Term Debt To Capitalization | 0.021 | Total Debt To Capitalization | 0.025 |
Latest news about Icosavax, Inc.
Icosavax, Inc. (ICVX) delivered earnings and revenue surprises of -3.64% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
The company's Q4 update made investors feel a little better after receiving disappointing news last week.
Icosavax Inc (NASDAQ: ICVX) has announced topline interim results from its ongoing Phase 1/2 trial of IVX-411, a VLP vaccine candidate displaying the SARS-CoV-2 receptor-binding domain (RBD). In the naïve setting, adjuvant effect on immunogenicity and a dose-response were.
SEATTLE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, today announced that Adam Simpson, Chief Executive Officer of Icosavax, will participate in two upcoming investor conferences.
We are now in the “digital era” of vaccine development, University of Washington researcher Neil King said at the GeekWire Summit in Seattle on Tuesday.
About Icosavax, Inc.
Description :
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.
